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Abstract The engineering of antigenic determinants on super 
secondary structures using de novo design approaches often in- 
volves synthesis of long peptide chains (35--80 residues long). This 
communication illustrates that the stabilization of secondary 
structure by rational design can also greatly enhance immunogen- 
icity and antigenicity, but in much shorter peptide sequences (21 
residues long). A peptide epitope the sequence of which has been 
derived from the C-terminus of the chicken riboflavin carrier 
protein (cRCP), H2N-Tyr-His-Ala-Cys-Gln-Lys-Lys-Leu-Leu- 
L~Phe-GIu-AIa-Lm-GIn-GIn-GIu-Giu-GIy-GIu-GIu-OH, has been 
chosen for analysis. Helical conformations were induced in the 
peptide in aqueous trifluoroetbanol. Analogs were designed to 
stabilize this conformation in water by either the introduction of 
appropriately spaced ion pairs or the strongly helix nucleating 
residue a-aminoisobutyric acid (Aib), substituted for Ala/Gly, 
thus affording a comparison of the helix stabilization strategies. 
Circular dichroism (CD) results demonstrate that all the designed 
analogs are appreciably more helical than the parent peptide in 
50% aqueous trifluoroethanol. Peptide antisera were raised for 
all analogs in rabbits. The affinities of these antisera for the 
native protein antigen, determined using a chaotrope disrupted 
binding assay, correlated very well with the helix content deter- 
mined by CD. 
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1. Introduction 
Riboflavin carrier protein (RCP) from chicken egg is a 219 
residue phosphoglycoprotein that is involved in transport and 
yolk deposition of the vitamin [16,17]. RCP is evolutionarily 
conserved and is critical for transplacental transport of the 
vitamin in pregnant mammals [18]. In vivo immunoneutraliza- 
tion of RCP has been shown to result in fetal resorption in 
rodents and curtailment of pregnancy in primates [19]. Anti- 
bodies to the C-terminal peptide of RCP are effective in neu- 
tralizing the protein in vivo. Preliminary conformational stud- 
ies of the native C-terminal peptide (Y-21) suggested that heli- 
cal conformations may be involved in determining peptide an- 
tigenicity [20]. Fig. 1 lists the sequence of the five 21 residue 
peptides examined in the present study. In all cases, the central 
segment of the peptide, QKKLLKFE,  was left unaltered since 
this has been implicated by epitope mapping to be important 
in binding to monoclonal antibodies (unpublished). The follow- 
ing strategies were adopted to stabilize helical conformations 
in the designed analogs. The incorporation of i~ i  + 3/i + 4 salt 
bridges involving lysine and glutamic acid pairs gave the pep- 
tide HC-21 [21]. This peptide was further engineered to have 
an N-terminal negatively charged residue (glutamic acid) to 
neutralize the helix dipole to give the peptide EC-21 [22]. The 
peptide HE-21 was designed with an extra i--+i + 3 ion pair 
near the N-terminus. In these three cases the design also abol- 
ishes the clustering of negative charges near the C-terminus, a
feature which may further enhance helix stability. The last 
peptide analog YAib-21 has the strongly helix promoting ~- 
aminoisobutyryl (Aib) residue as replacements for glycine and 
alanine residues [23-25]. 
The observation that antibodies raised to short synthetic 
peptide fragments often cross react with the native protein 
antigens has stimulated a great deal of interest in the develop- 
ment of peptide vaccines [14]. Well-defined conformational 
states have been demonstrated for a wide variety of antigenic 
peptides in solution [5]. Transferred NOE [6-9] and crystallo- 
graphic [10,11] studies of peptides complexed to Fab fragments 
of monoclonal antibodies have clearly demonstrated the forma- 
tion of ordered backbone conformations in the bound states. 
The incorporation of specific stereochemical constraints into 
an antigenic peptide that stabilize conformational states recog- 
nized by antibodies, appears to provide an attractive approach 
to engineering improved immunological characteristics [ 12-15]. 
We describe in this report hat helix stabilization i a 21 residue 
synthetic peptide fragment of chicken riboflavin carrier protein 
(cRCP) dramatically enhances the immunogenic properties of 
the peptide. 
*Corresponding author. Molecular Biophysics Unit, Indian Institute of 
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2. Materials and methods 
The peptides were synthesized on a LKB-Biolynx 4175 semi-auto- 
matic peptide synthesiser using Fmoc chemistry. Sidechain protecting 
groups were cleaved along with the peptide from the resin by treatment 
with 95% aqueous TFA for 3 h. Analytical HPLC on a Lichrosorb C18 
column (4 × 250 ram, 5 pM particle size) showed the peptide to be 
>98% pure. Solvent systems used were solvent A: 0.1% TFA in 
water; solvent B: 100% acetonitrile containing 0.1% TFA. A linear 
gradient of 5-40% in 40 rain was used (flow rate 0.8 ml/min, detection 
at 226 nm, retention times ranged between 26-28 min). The peptide 
identity was confirmed by either sequencing or mass spectroscopy. All 
CD spectra were recorded on a JASCO-J-500A spectropolarimeter 
using a cell of path length 1 mm at ambient emperature. Peptide 
concentrations (~ 0.22/tM) were determined by tyrosine absorbance at 
275 nm (t~275 =1,340 M -~ .cm-J). Peptides were conjugated to diphthe- 
ria toxoid (DT) through their N-terminal tyrosine residues using bis- 
diazotised benzidine [26]. Peptide antisera were raised by immunizing 
rabbits ubcutaneously with 500/tg of peptide-DT conjugate mulsified 
with 2 volumes of complete Freund's adjuvant. Animals were boosted 
(250/~g) at 20 day intervals and test bleeds were collected ten days 
following a booster injection. Antibody titers were estimated by coating 
the respective peptides on to a 96-well polystyrene microtitre plates at 
concentration of 20 ~tg/ml in 0.1 M phosphate buffer, pH 7.2, contain- 
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YHAC!QKKLLKFE 
YHAC QKKLLKFE 
YHAE 'QKKLLKFE 
YEAC[QKKLLKFE 
YHUC ! QKKLLKFE 
ALQQEEGEE Y-21 
AL I=QEKGKE HC-21 
AL I=QEKGKE HE-21 
ALEQEKGKE EC-21 
L ILQQEEUEE YAib-21 
t ig. 1. Sequences of the peptides tudied. The residues in the epitopic 
r~:gion have been boxed. The replacements made in the design of the 
aaalogs are shown in bold type. Single letter code used: A, alanine; 
( , S-acetamidomethyl c steine; E, glutamic acid; F, phenylalanine; 
( r, glycine; H, histidine; K, lysine; L, leucine; Q, glutamine; U, ~z-ami- 
1 oisobutyric acid; Y, tyrosine. 
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Fig. 2. Circular dichroism spectra of the peptides in 50% 2,2,2- 
trifluoroethanol-100 mM phosphate buffer (pH 7.0). Peptide concen- 
trations were in the range of 0.22 raM. CD band intensities are plotted 
as molar ellipticities in deg'cm2"dmol -~. Y-21 ( --), YAib-21 
( . . . .  ), HC-21 ( - - - ) ,  EC-21 ( - . . )  and HE-21 ( ..... ). 
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Fig. 3. Plot of the molar ellipticity at 222 nm ([022z]Mldeg" cm 2" dmol -I) 
as monitored by circular dichroism versus the relative affinity indices 
of the antisera. Resistance to thiocyanate elution in a variation of the 
standard ELISA [15] was utilized as a measure of affinity, the index 
representing the molar concentration of NH4SCN required to bring 
about 50% reduction in initial absorbance. A, Y-21; I, YAib-21; 
*, HC-21; o, EC-21; x, HE-21. 
ing 150 mM NaC1 for 2 h. The unoccupied sites were blocked with 0.1 
M phosphate buffer containing 150 mM NaC1 and 0.5% BSA for 1 h, 
followed by incubation with antipeptide antisera ppropriately diluted 
in the same buffer for 2 h at 37°C. Thereafter anti rabbit IgG conju- 
gated to alkaline phosphatase (1 : 1,000 dilution) was added. The bind- 
ing of the antibody was quantitated using p-nitrophenylphosphate (1 
mg/ml) in 1 M diethanolamine-HCl buffer, pH 9.8, containing 0.5 mM 
MgC12 as substrate. Relative affinities of the peptide antibodies to the 
native protein were estimated by the method of Macdonald et al. using 
thiocyanate elution [27]. 
3. Resu l t s  and  d iscuss ion  
Fig. 2 shows the far UV circular dichroic (CD) spectra of all 
the five peptides in 50% aqueous 2,2,2-trifluoroethanol (TFE). 
Enhanced helicity as determined by the intensity of the 208 and 
222 nm bands is observed for all the designed analogs as com- 
pared to the native Y-21. The synthetic peptides did not show 
appreciable helicity in aqueous buffers but required addition of 
at least 20% TFE  to induce stable secondary structures. Poly- 
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clonal antisera were raised to peptide-diphtheria toxoid conju- 
gates [26] in rabbits and their cross reactivity evaluated against 
the native protein and various peptide antigens. Fig. 3 shows 
a plot of molar ellipticity at 222 nm versus the affinities of their 
antisera to the native protein antigen, as estimated using a 
chaotropic agent ammoniumthiocyanate [27]. A very good cor- 
relation is observed between the helicity of the peptide antigen 
and the relative affinities of the derived antibody for the native 
protein, with similar affinities being observed for the analogs 
with the highest helical content. Besides, the antibody titers 
were higher in the case of designed analogs uggesting enhance- 
ment of both immunogenicity and antigenicity. A further point 
of interest is that antibodies raised to the native, flexible anti- 
genic peptide (Y-21) bind weakly to the conformationally con- 
strained antigen (YAib-21). In contrast, antibodies raised to the 
more ordered peptide YAib-21 bind strongly to the flexible 
native peptide Y-21 (manuscript in preparation). Both sets of 
antibodies bind to the native protein. These results uggest that 
induced fit of the flexible antigen at the antibody combining 
sites may be operative [8]. 
The above results conclusively demonstrate hat the presen- 
tation of the epitope on a helical scaffolding has greatly en- 
hanced the affinity of the corresponding antibodies to the na- 
tive protein antigen. In the past, attempts to engineer antigenic 
determinants have focussed mainly on super secondary struc- 
tures [12-15]. While these strategies have their own merits, one 
drawback lies in the fact that the designed sequences are quite 
long (often in the range of 35-80 residues). The present strategy 
however, emphasizes the stabilization of relatively short pep- 
tide fragments. Thus the speed and ease of such syntheses 
together with simple design principles hould greatly simplify 
the construction of conformationally defined epitopes. 
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